We are live on ! Find out more
BLFS icon

BioLife Solutions

187 hedge funds and large institutions have $1.18B invested in BioLife Solutions in 2025 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 59 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.91% more ownership

Funds ownership: 100.74%101.66% (+0.91%)

0% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 25

4% less capital invested

Capital invested by funds: $1.23B → $1.18B (-$43.9M)

3% less funds holding

Funds holding: 192187 (-5)

20% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 74

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
187
Holders Change
-5
Holders Change %
-2.6%
% of All Funds
2.26%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
25
Increased
59
Reduced
74
Closed
25
Calls
$27K
Puts
Net Calls
+$27K
Net Calls Change
-$320K

BLFS Hedge Fund Activity: Q4 2025 in Review

187 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q4 2025, worth a combined $1.18B — down 3.6% from $1.23B a quarter earlier.

Fund positioning in BLFS was balanced in Q4 2025: 25 funds opened new positions, 25 closed out, 59 added to existing stakes and 74 trimmed.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $29.1M. The largest seller was Casdin Capital, cutting an estimated $19.6M.

  • 187 institutional investors held BioLife Solutions (BLFS) as of Q4 2025, down from 192 in Q3 2025.
  • Funds reported $1.18B of BioLife Solutions stock for Q4 2025, down 3.6% quarter-over-quarter.
  • 25 funds opened new BioLife Solutions positions in Q4 2025 and 25 closed out, a net change of 0 holders.
  • The largest BioLife Solutions buyer in Q4 2025 was T. Rowe Price Investment Management, an estimated $29.1M added.
  • The largest BioLife Solutions seller in Q4 2025 was Casdin Capital, an estimated $19.6M sold.

Based on aggregated 13F filings for Q4 2025.